Prednisone Administration in Quiescent COPD Patients to Determine the Effect on Gene Expression

• Register: ClinicalTrials.gov
• Last refreshed on: 10 May 2021
• Main ID: NCT02534402
• Date of registration: 26/08/2015
• Prospective Registration: No
• Primary sponsor: University of British Columbia
• Public title: Prednisone Administration in Quiescent COPD Patients to Determine the Effect on Gene Expression
• Scientific title: Clinical Implementation and Outcomes Evaluation of Blood-Based Biomarkers for COPD Management: COPD Prednisone Sub-Study
• Date of first enrolment: August 2015
• Target sample size: 40
• Recruitment status: Active, not recruiting
• URL: https://clinicaltrials.gov/show/NCT02534402
• Study type: Interventional
• Study design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: None (Open Label).
• Phase: Phase 4

Countries of recruitment

Canada

Contacts

• Name: Donald D Sin, MD, MPH
• Affiliation: University of British Columbia, St. Paul's Hospital, James Hogg Research Centre

Key inclusion & exclusion criteria

Inclusion Criteria:

- Participants diagnosed with COPD

Exclusion Criteria:

- Participants currently taking prednisone

- Participants who received prednisone within the last 2 weeks

- Participants who were hospitalized in the last 2 weeks for COPD or a related
respiratory condition



Age minimum: 19 Years
Age maximum: 95 Years
Gender: All

Health Condition(s) or Problem(s) studied

Chronic Obstructive Pulmonary Disease

Intervention(s)

Drug: Prednisone

Primary Outcome(s)

Effect of prednisone on peripheral whole blood gene expression [Time Frame: Period of 5 days]

Secondary ID(s)

H15-01147

Source(s) of Monetary Support

Please refer to primary and secondary sponsors